All Phenotypes Jak2<tm1Mohi> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Jak2^tm1Mohi/Jak2⁺ Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA	MGI:5320790
cn2	Jak2^tm1Mohi/Jak2^tm1Mohi Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA	MGI:5320791

Allelic Composition	Jak2^tm1Mohi/Jak2⁺ Tg(Mx1-cre)1Cgn/0
Genetic Background	involves: C57BL/6 * CBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Jak2^tm1Mohi mutation (0 available); any Jak2 mutation (57 available)
Tg(Mx1-cre)1Cgn mutation (7 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

enlarged spleen ( J:183821 )

• intermediate in pIpC-treated mice

increased spleen weight ( J:183821 )

• intermediate in pIpC-treated mice

myeloid hyperplasia ( J:183821 )

• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice

abnormal bone marrow cell morphology/development ( J:183821 )

• intermediate increased myeloid, megakaryocyte/erythroid and granulocyte/macrophage progenitors in the bone marrow and spleen of pIpC-treated mice

• increased granulocyte-macrophage progenitors in the spleen of pIpC-treated mice

abnormal common myeloid progenitor cell morphology ( J:183821 )

• increased myeloid progenitors in the spleen of pIpC-treated mice

increased megakaryocyte cell number ( J:183821 )

• in the splenic red pulp of pIpC-treated mice

increased erythroid progenitor cell number ( J:183821 )

• in the splenic red pulp of pIpC-treated mice

• 10-fold increase in CD71/Ter-119+ cells in the spleen of pIpC-treated mice

• intermediate in the bone marrow and spleen of pIpC-treated mice

increased erythrocyte cell number ( J:183821 )

• intermediate in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks

polycythemia ( J:183821 )

• intermediate in pIpC-treated mice

increased hematocrit ( J:183821 )

• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks

increased hemoglobin content ( J:183821 )

• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks

microcytosis ( J:183821 )

• in pIpC-treated mice

thrombocytosis ( J:183821 )

• intermediate in pIpC-treated mice

decreased B cell number ( J:183821 )

• in the bone marrow and spleen of pIpC-treated mice

increased leukocyte cell number ( J:183821 )

• intermediate in pIpC-treated mice

increased neutrophil cell number ( J:183821 )

• intermediate in pIpC-treated mice

reticulocytosis ( J:183821 )

• intermediate in pIpC-treated mice

increased hematopoietic stem cell number ( J:183821 )

• in the bone marrow and spleen of pIpC-treated mice

abnormal spleen red pulp morphology ( J:183821 )

• slight reticulin fibrosis in pIpC-treated mice

increased spleen red pulp amount ( J:183821 )

• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors

abnormal spleen white pulp morphology ( J:183821 )

• fibrosis in pIpC-treated mice

spleen fibrosis ( J:183821 )

• fibrosis in the splenic red and white pulp of pIpC-treated mice

immune system

enlarged spleen ( J:183821 )

• intermediate in pIpC-treated mice

increased spleen weight ( J:183821 )

• intermediate in pIpC-treated mice

myeloid hyperplasia ( J:183821 )

• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice

decreased B cell number ( J:183821 )

• in the bone marrow and spleen of pIpC-treated mice

increased leukocyte cell number ( J:183821 )

• intermediate in pIpC-treated mice

increased neutrophil cell number ( J:183821 )

• intermediate in pIpC-treated mice

abnormal spleen red pulp morphology ( J:183821 )

• slight reticulin fibrosis in pIpC-treated mice

increased spleen red pulp amount ( J:183821 )

• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors

abnormal spleen white pulp morphology ( J:183821 )

• fibrosis in pIpC-treated mice

spleen fibrosis ( J:183821 )

• fibrosis in the splenic red and white pulp of pIpC-treated mice

skeleton

abnormal bone marrow cavity morphology ( J:183821 )

• mild fibrosis in older pIpC-treated mice

myelofibrosis ( J:183821 )

• fibrosis in the bone marrow cavity of pIpC-treated mice

growth/size/body

enlarged spleen ( J:183821 )

• intermediate in pIpC-treated mice

increased spleen weight ( J:183821 )

• intermediate in pIpC-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
polycythemia vera		DOID:8997	OMIM:263300	J:183821

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

enlarged spleen ( J:183821 )

• in pIpC-treated mice

increased spleen weight ( J:183821 )

• in pIpC-treated mice

myeloid hyperplasia ( J:183821 )

• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice

abnormal bone marrow cell morphology/development ( J:183821 )

• increased myeloid, megakaryocyte/erythroid and granulocyte/macrophage progenitors in the bone marrow and spleen of pIpC-treated mice

• increased granulocyte-macrophage progenitors in the spleen of pIpC-treated mice

abnormal common myeloid progenitor cell morphology ( J:183821 )

• increased myeloid progenitors in the spleen of pIpC-treated mice

decreased bone marrow cell number ( J:183821 )

• in pIpC-treated mice with trilineage hyperplasia

increased megakaryocyte cell number ( J:183821 )

• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors

increased erythroid progenitor cell number ( J:183821 )

• in the splenic red pulp of pIpC-treated mice

• 20-fold increase in CD71/Ter-119+ cells in the spleen of pIpC-treated mice

• in the bone marrow and spleen of pIpC-treated mice

increased erythrocyte cell number ( J:183821 )

• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks

polycythemia ( J:183821 )

• in pIpC-treated mice

increased hematocrit ( J:183821 )

• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks

increased hemoglobin content ( J:183821 )

• in pIpC-treated mice within 4 weeks and sustained for more than 20 weeks

microcytosis ( J:183821 )

• in pIpC-treated mice

thrombocytosis ( J:183821 )

• in pIpC-treated mice

decreased B cell number ( J:183821 )

• in the bone marrow and spleen of pIpC-treated mice

increased leukocyte cell number ( J:183821 )

• in pIpC-treated mice

increased neutrophil cell number ( J:183821 )

• in pIpC-treated mice

reticulocytosis ( J:183821 )

• in pIpC-treated mice

increased hematopoietic stem cell number ( J:183821 )

• in the bone marrow and spleen of pIpC-treated mice

abnormal spleen red pulp morphology ( J:183821 )

• reticulin fibrosis in pIpC-treated mice

increased spleen red pulp amount ( J:183821 )

• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors

abnormal spleen white pulp morphology ( J:183821 )

• fibrosis in pIpC-treated mice

decreased spleen white pulp amount ( J:183821 )

• in pIpC-treated mice

spleen fibrosis ( J:183821 )

• fibrosis in the splenic red and white pulp of pIpC-treated mice

immune system

enlarged spleen ( J:183821 )

• in pIpC-treated mice

increased spleen weight ( J:183821 )

• in pIpC-treated mice

myeloid hyperplasia ( J:183821 )

• increased Gr-1/Mac-1+ cells in the spleen of pIpC-treated mice

decreased B cell number ( J:183821 )

• in the bone marrow and spleen of pIpC-treated mice

increased leukocyte cell number ( J:183821 )

• in pIpC-treated mice

increased neutrophil cell number ( J:183821 )

• in pIpC-treated mice

abnormal spleen red pulp morphology ( J:183821 )

• reticulin fibrosis in pIpC-treated mice

increased spleen red pulp amount ( J:183821 )

• in pIpC-treated mice with increased number of megakaryocytes and clusters of immature erythroid precursors

abnormal spleen white pulp morphology ( J:183821 )

• fibrosis in pIpC-treated mice

decreased spleen white pulp amount ( J:183821 )

• in pIpC-treated mice

spleen fibrosis ( J:183821 )

• fibrosis in the splenic red and white pulp of pIpC-treated mice

skeleton

abnormal bone marrow cavity morphology ( J:183821 )

• fibrosis in pIpC-treated mice

myelofibrosis ( J:183821 )

• fibrosis in the bone marrow cavity of pIpC-treated mice

growth/size/body

enlarged spleen ( J:183821 )

• in pIpC-treated mice

increased spleen weight ( J:183821 )

• in pIpC-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
polycythemia vera		DOID:8997	OMIM:263300	J:183821

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 05/07/2024 MGI 6.23